FRAX(R) and its applications to clinical practice

WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
Bone (Impact Factor: 3.97). 03/2009; 44(5):734-43. DOI: 10.1016/j.bone.2009.01.373
Source: PubMed


The introduction of the WHO FRAX algorithms has facilitated the assessment of fracture risk on the basis of fracture probability. FRAX integrates the influence of several well validated risk factors for fracture with or without the use of BMD. Its use in fracture risk prediction poses challenges for patient assessment, the development of practice guidelines, the evaluation of drug efficacy and reimbursement, as well as for health economics which are the topics outlined in this review.

25 Reads
  • Source
    • "These findings were also consistent with the main results using the whole population (Table 2), implying no significant effect of the baseline anti-osteoporotic treatment and/or supplementation on the prediction of FRAX and FI in major osteoporotic fracture. Some studies argued that previous falls should be included into FRAX, since previous falls were an independent and significant risk factor for future fractures [12] [28]. Nevertheless, evidence showed that models incorporating falls as a risk factor may not be superior to FRAX alone in predicting future risk of fractures [41]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A frailty index (FI) of deficit accumulation could quantify and predict the risk of fractures based on the degree of frailty in the elderly. We aimed to compare the predictive powers between the FI and the fracture risk assessment tool (FRAX) in predicting risk of major osteoporotic fracture (hip, upper arm or shoulder, spine, or wrist) and hip fracture, using the data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) 3-year Hamilton cohort. There were 3,985 women included in the study, with the mean age of 69.4 years (standard deviation [SD] = 8.89). During the follow-up, there were 149 (3.98%) incident major osteoporotic fractures and 18 (0.48%) hip fractures reported. The FRAX and FI were significantly related to each other. Both FRAX and FI significantly predicted risk of major osteoporotic fracture, with a hazard ratio (HR) of 1.03 (95% confidence interval [CI]: 1.02-1.05) and 1.02 (95% CI: 1.01-1.04) for per-0.01 increment for the FRAX and FI respectively. The HRs were 1.37 (95% CI: 1.19 - 1.58) and 1.26 (95% CI: 1.12 - 1.42) for an increase of per-0.10 (approximately one SD) in the FRAX and FI respectively. Similar discriminative ability of the models was found: c-index = 0.62 for the FRAX and c-index = 0.61 for the FI. When cut-points were chosen to trichotomize participants into low-risk, medium-risk and high-risk groups, a significant increase in fracture risk was found in the high-risk group (HR = 2.04, 95% CI: 1.36-3.07) but not in the medium-risk group (HR = 1.23, 95% CI: 0.82-1.84) compared with the low-risk women for the FI, while for FRAX the medium-risk (HR = 2.00, 95% CI: 1.09-3.68) and high-risk groups (HR = 2.61, 95% CI: 1.48-4.58) predicted risk of major osteoporotic fracture significantly only when survival time exceeded 18 months (550 days). Similar findings were observed for hip fracture and in sensitivity analyses. In conclusion, the FI is comparable with FRAX in the prediction of risk of future fractures, indicating that measures of frailty status may aid in fracture risk assessment and fracture prevention in the elderly. Further evidence from randomized controlled trials of osteoporosis medication interventions is needed to support the FI and FRAX as validated measures of fracture risk. Copyright © 2015. Published by Elsevier Inc.
    Bone 04/2015; 77. DOI:10.1016/j.bone.2015.04.028 · 3.97 Impact Factor
  • Source
    • "Giving the same weighted value for patients who took different dose of glucocorticoid it was inappropriate for the assessment of osteoporotic fracture risk. A recent study suggested the guideline for the adjustment of the FRAX model to the dose of glucocorticoids (25, 26). According to that study, the probability of major fractures decreased by about 20%, depending on age in cases of low dose exposure (<2.5 mg prednisolone daily or equivalent). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the current study is to identify patients without osteoporosis who met the criteria of the fracture risk assessment tool (FRAX) of the National Osteoporosis Foundation (NOF) only. The incidence of fractures was investigated in patients who met only the FRAX criteria of the NOF and patients who presented osteoporosis. Five hundred and forty five patients with rheumatoid arthritis who visited a single center were recruited in Korea. In the follow-up period of median 30 months, the new onset of fractures was investigated. Of 223 patients who have no osteoporosis, 39 (17.4%) satisfied the FRAX criteria for pharmacological intervention. During the follow-up period, 2 new onset fractures occurred in patients who met only the FRAX criteria and 22 new onset fractures did in patients with osteoporosis by bone mineral density. The incidence rate for new onset fractures of patients who met only the FRAX criteria was with 295.93 per 10,000 person-years higher than in the general population with 114.99 per 10,000 person-years. Patients who met the FRAX criteria of the NOF only need pharmacological intervention because their numbers of incidence for new onset fractures are similar to those of patients with osteoporosis by BMD. Graphical Abstract
    Journal of Korean Medical Science 08/2014; 29(8):1082-9. DOI:10.3346/jkms.2014.29.8.1082 · 1.27 Impact Factor
  • Source
    • "Recently, the fracture risk assessment (FRAX) algorithm has been developed by the WHO, which could assess the fracture risk of an individual even if BMD is not measured [109]. This algorithm integrates the influence of several well-validated risk factors for fractures that are independent of BMD and therefore it might be useful for the case-finding strategy that identifies diabetic patients at high risk for fracture. "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is well established that osteoporosis and diabetes are prevalent diseases with significant associated morbidity and mortality. Patients with diabetes mellitus have an increased risk of bone fractures. In type 1 diabetes, the risk is increased by ∼6 times and is due to low bone mass. Despite increased bone mineral density (BMD), in patients with type 2 diabetes the risk is increased (which is about twice the risk in the general population) due to the inferior quality of bone. Bone fragility in type 2 diabetes, which is not reflected by bone mineral density, depends on bone quality deterioration rather than bone mass reduction. Thus, surrogate markers and examination methods are needed to replace the insensitivity of BMD in assessing fracture risks of T2DM patients. One of these methods can be trabecular bone score. The aim of the paper is to present the present state of scientific knowledge about the osteoporosis risk in diabetic patient. The review also discusses the possibility of problematic using the study conclusions in real clinical practice.
    International Journal of Endocrinology 06/2014; 2014(3):820615. DOI:10.1155/2014/820615 · 1.95 Impact Factor
Show more